Overview
FBRX market data
Price History
FBRX price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$4.71 Diluted earnings per share over the trailing twelve months.
- Beta
- 2.28 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -158,775.0% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $9.91 – $77.20 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $1.6B · P/B 5.60 · P/S 39,368.96.
Company News
argenx Announces Commencement of Tender Offer to Acquire Forte Biosciences, Inc.Globenewswire Inc · Aug 6, 2026, 12:15 PM
argenx Commences $77/Shr Cash Tender Offer Through Subsidiary Avena Merger Sub To Acquire All Outstanding Shares Of Forte BiosciencesBenzinga · Aug 6, 2026, 11:59 AM
Halper Sadeh LLC is Investigating Whether FBRX, LXFR, SMTI, MKTX are Obtaining Fair Deals for their ShareholdersGlobenewswire Inc · Aug 5, 2026, 8:15 PM
Halper Sadeh LLC is Investigating Whether FBRX and SAFT are Obtaining Fair Deals for their ShareholdersGlobenewswire Inc · Jul 29, 2026, 11:00 AM
Barclays Downgrades Forte Biosciences to Equal-Weight, Raises Price Target to $77Benzinga · Jul 28, 2026, 10:52 AM
Crude Oil Falls Sharply; US Durable Goods Orders Increase 0.3% In JuneBenzinga · Jul 27, 2026, 4:22 PM
Argenx Secures Promising Autoimmune Drug In Forte Biosciences TakeoverBenzinga · Jul 27, 2026, 4:16 PM
Forte Biosciences shares are trading higher after the company announced argenx will acquire it for $77 per share in cash, representing a total equity value of ~$2.2 billion.Benzinga · Jul 27, 2026, 2:50 PM
Baker Hughes Posts Upbeat Q2 Earnings, Joins Forte Biosciences, Eikon Therapeutics And Other Big Stocks Moving Higher On MondayBenzinga · Jul 27, 2026, 2:35 PM
8-K filing — Forte Biosciences, Inc. (FBRX)SEC EDGAR · Jul 27, 2026, 10:06 AM